Knight Therapeutics develops, manufactures, acquires, and markets pharmaceutical products, consumer health products, and medical devices globally. Products include Tafasitamab for lymphoma and Pemigatinib for cholangiocarcinoma. Other products treat various cancers, including breast, prostate, and pancreatic cancer. The company also offers treatments for multiple myeloma, myelodysplastic syndrome, and other conditions. Knight Therapeutics provides additional treatments for fungal infection, leishmaniasis, HIV infection, dementia, and irritable bowel syndrome. The company finances life science companies and invests in venture capital funds.
| Indicator | Value |
|---|---|
| PER | 139.7 |
| EV/EBITDA | 8.0 |
| Price/Free Cash Flow' | 125.9 |
| ROIC | 4.3% |
| Net Debt/EBITDA | 100.0 |